[1]Tromp G, Kuivaniemi H, Raphael S, et al. Genetic linkage of familial granulomatous inflammatory arthritis, skin rash, and uveitis to chromosome 16[J]. Am J Hum Genet, 1996, 59: 1097-1107. PMID: 8900239. [2]Inohara, Chamaillard, McDonald C, et al. NOD-LRR proteins: role in host-microbial interactions and inflammatory disease[J]. Annu Rev Biochem, 2005, 74: 355-383. doi: 10.1146/annurev.biochem.74.082803.133347. [3]李彩凤,张俊梅,李士朋,等.中国儿童Blau综合征患者基因突变及临床表型研究[J]. 中国科学:生命科学, 2018, 48: 962-966. [4]Napier RJ, Lee EJ, Davey MP, et al. T cell-intrinsic role for Nod2 in protection against Th17-mediated uveitis[J]. Nat Commun, 2020, 26: 5406. doi: 10.1038/s41467-020-18961-0. [5]Nishiyama M, Li HJ, Okafuji I, et al. Sustained surface ICAM-1 expression and transient PDGF-B production by phorbol myristate acetate-activated THP-1 cells harboring Blau syndrome-associated NOD2 mutations[J]. Children, 2021, 8: 335. doi: 10.3390/children8050335. [6]Arakawa A, Kambe N, Nishikomori R, et al. NOD2 Mutation-associated case with Blau syndrome triggered by BCG vaccination[J]. Children, 2021, 8: 117. doi: 10.3390/children8020117. [7]Kitagawa Y, Kawasaki Y, Yamasaki Y, et al. Anti-TNF treatment corrects IFN-γ-dependent proinflammatory signatures in Blau syndrome patient-derived macrophages[J]. J Allergy Clin Immunol, 2022, 149: 176-188. doi: 10.1016/j.jaci.2021.05.030. [8]Saito MK. Elucidation of the pathogenesis of autoinflammatory diseases using iPS cells[J]. Children, 2021, 8: 94. doi: 10.3390/children8020094. [9]Thirumal Kumar D, Udhaya Kumar S, Nishaat Laeeque AS, et al. Computational model to analyze and charac-terize the functional mutations of NOD2 protein causing inflammatory disorder-Blau syndrome[J]. Adv Protein Chem Struct Biol, 2020, 120: 379-408. doi: 10.1016/bs.apcsb.2019.11.005. [10]Wang W, Wang W, Zhong LQ, et al. Thalidomide may be an effective drug for Blau syndrome: a case report[J]. Ann Palliat Med, 2022, 11: 2538-2543. doi: 10.21037/apm-21-2216. [11]Zhang S, Cai Z, Mo X, et al. Tofacitinib effectiveness in Blau syndrome: a case series of Chinese paediatric patients[J]. Pediatr Rheumatol Online, 2021, 19: 160. doi: 10.1186/s12969-021-00634-x. [12]Matsuda T, Kambe N, Takimoto-Ito R, et al. Potential benefits of TNF targeting therapy in Blau syndrome, a NOD2-associated systemic autoinflammatory granulomatosis[J]. Front Immunol, 2022, 13: 895765. doi: 10.3389/fimmu.2022.895765. |